Indiana-based pharmaceutical giant Eli Lilly revealed that its experimental Alzheimer's drug failed to achieve its primary objective of stopping the spread of the disease but revealed that it did manage to slow down the mental deterioration in patients affected with a mild form of the disease. Lilly was conducting two large clinical trials to test the effectiveness of solanezumab, which attacked a protein known as beta amyloid that produces toxic effects on the brain ...For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com
No comments:
Post a Comment